In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide
Lisa C Rohan, Bernard J Moncla, Ratiya Pamela Kunjara Na Ayudhya, Marilyn Cost, Yunda Huang, Fang Gai, Nicole Billitto, J D Lynam, Kara Pryke, Phillip Graebing, Nicole Hopkins, James F Rooney, David Friend, Charlene S Dezzutti, Lisa C Rohan, Bernard J Moncla, Ratiya Pamela Kunjara Na Ayudhya, Marilyn Cost, Yunda Huang, Fang Gai, Nicole Billitto, J D Lynam, Kara Pryke, Phillip Graebing, Nicole Hopkins, James F Rooney, David Friend, Charlene S Dezzutti
Abstract
Background: Tenofovir gel has entered into clinical trials for use as a topical microbicide to prevent HIV-1 infection but has no published data regarding pre-clinical testing using in vitro and ex vivo models. To validate our findings with on-going clinical trial results, we evaluated topical tenofovir gel for safety and efficacy. We also modeled systemic application of tenofovir for efficacy.
Methods and findings: Formulation assessment of tenofovir gel included osmolality, viscosity, in vitro release, and permeability testing. Safety was evaluated by measuring the effect on the viability of vaginal flora, PBMCs, epithelial cells, and ectocervical and colorectal explant tissues. For efficacy testing, PBMCs were cultured with tenofovir or vehicle control gels and HIV-1 representing subtypes A, B, and C. Additionally, polarized ectocervical and colorectal explant cultures were treated apically with either gel. Tenofovir was added basolaterally to simulate systemic application. All tissues were challenged with HIV-1 applied apically. Infection was assessed by measuring p24 by ELISA on collected supernatants and immunohistochemistry for ectocervical explants. Formulation testing showed the tenofovir and vehicle control gels were >10 times isosmolar. Permeability through ectocervical tissue was variable but in all cases the receptor compartment drug concentration reached levels that inhibit HIV-1 infection in vitro. The gels were non-toxic toward vaginal flora, PBMCs, or epithelial cells. A transient reduction in epithelial monolayer integrity and epithelial fracture for ectocervical and colorectal explants was noted and likely due to the hyperosmolar nature of the formulation. Tenofovir gel prevented HIV-1 infection of PBMCs regardless of HIV-1 subtype. Topical and systemic tenofovir were effective at preventing HIV-1 infection of explant cultures.
Conclusions: These studies provide a mechanism for pre-clinical prediction of safety and efficacy of formulated microbicides. Tenofovir was effective against HIV-1 infection in our algorithm. These data support the use of tenofovir for pre-exposure prophylaxis.
Conflict of interest statement
Competing Interests: JFR is an employee of Gilead Sciences, and DF is an employee of CONRAD; both provided tenofovir and vehicle control gels and tenofovir drug. Neither Gilead nor CONRAD has provided funding for this study. Both supplied study product only that was evaluated. This will not affect the authors' ability to share data. The remaining authors have no competing interests.
Figures
References
- UNAIDS/WHO. Geneva: UNAIDS.; 2008. Report on global AIDS epidemic.362
- Gray RH, Wawer MJ, Polis CB, Kigozi G, Serwadda D. Male Circumcision and Prevention of HIV and Sexually Transmitted Infections. Curr Infect Dis Rep. 2008;10:121–127.
- Mills E, Cooper C, Anema A, Guyatt G. Male circumcision for the prevention of heterosexually acquired HIV infection: a meta-analysis of randomized trials involving 11,050 men. HIV Med. 2008;9:332–335.
- Steinbrook R. One step forward, two steps back–will there ever be an AIDS vaccine? N Engl J Med. 2007;357:2653–2655.
- Celum C, Wald A, Hughes J, Sanchez J, Reid S, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:2109–2119.
- Greig FE, Koopman C. Multilevel analysis of women's empowerment and HIV prevention: quantitative survey Results from a preliminary study in Botswana. AIDS Behav. 2003;7:195–208.
- Kalichman SC, Williams EA, Cherry C, Belcher L, Nachimson D. Sexual coercion, domestic violence, and negotiating condom use among low-income African American women. J Womens Health. 1998;7:371–378.
- Carballo-Dieguez A, Miner M, Dolezal C, Rosser BR, Jacoby S. Sexual negotiation, HIV-status disclosure, and sexual risk behavior among Latino men who use the internet to seek sex with other men. Arch Sex Behav. 2006;35:473–481.
- Olmsted SS, Khanna KV, Ng EM, Whitten ST, Johnson ON, 3rd, et al. Low pH immobilizes and kills human leukocytes and prevents transmission of cell-associated HIV in a mouse model. BMC Infect Dis. 2005;5:79.
- Tuyama AC, Cheshenko N, Carlucci MJ, Li JH, Goldberg CL, et al. ACIDFORM inactivates herpes simplex virus and prevents genital herpes in a mouse model: optimal candidate for microbicide combinations. J Infect Dis. 2006;194:795–803.
- Abdool Karim S, Coletti A, Richardson B, Ramjee G, Hoffman I, et al. Safety and effectiveness of vaginal microbicides BufferGel and 0.5% PRO 2000/5 gel for the prevention of HIV infection in women: results from the HPTN 035 trial. CROI 2009; Montreal, Canada. Abst 48LB.
- Moszynski P. Halt to microbicide trial sets back AIDS research. BMJ. 2007;334:276.
- Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359:463–472.
- Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1977–1987.
- Microbicide Development Programme. HIV ‘prevention’ gel PRO 2000 proven ineffective. 2009 , accessed Dec. 22, 2009.
- Palmer S, Margot N, Gilbert H, Shaw N, Buckheit R, Jr, et al. Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance. AIDS Res Hum Retroviruses. 2001;17:1167–1173.
- Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, et al. Prevention of SIV Rectal Transmission and Priming of T Cell Responses in Macaques after Local Pre-exposure Application of Tenofovir Gel. PLoS Med. 2008;5:e157.
- Parikh UM, Dobard C, Sharma S, Cong ME, Jia H, et al. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol. 2009;83:10358–10365.
- Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006;20:543–551.
- Hillier SL. Safety and acceptability of coitally dependant use of 1% tenofovir over six months of use; Microbicides 2008; New Delhi, India. Abst 655.
- Cosentino LA, Landers DV, Hillier SL. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by strand displacement amplification and relevance of the amplification control for use with vaginal swab specimens. J Clin Microbiol. 2003;41:3592–3596.
- Antonio MA, Hawes SE, Hillier SL. The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species. J Infect Dis. 1999;180:1950–1956.
- Moncla BJ, Braham P, Rabe LK, Hillier SL. Rapid presumptive identification of black-pigmented gram-negative anaerobic bacteria by using 4-methylumbelliferone derivatives. J Clin Microbiol. 1991;29:1955–1958.
- Moncla BJ, Hillier SL. Why nonoxynol-9 may have failed to prevent acquisition of Neisseria gonorrhoeae in clinical trials. Sex Transm Dis. 2005;32:491–494.
- Moncla BJ, Pryke K, Isaacs CE. Killing of Neisseria gonorrhoeae, Streptococcus agalactiae (group B streptococcus), Haemophilus ducreyi and vaginal Lactobacillus by 3-O-octyl-sn-glycerol. Antimicrob Agents Chemother. 2008;52:1023–1027.
- Fogh J, Wright WC, Loveless JD. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst. 1977;58:209–214.
- Kuramoto H. Studies of the growth and cytogenetic properties of human endometrial adenocarcinoma in culture and its development into an established line. Acta Obstet Gynaecol Jpn. 1972;19:47–58.
- Dezzutti CS, James VN, Ramos A, Sullivan ST, Siddig A, et al. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob Agents Chemother. 2004;48:3834–3844.
- Abner SR, Guenthner PC, Guarner J, Hancock KA, Cummins JE, Jr, et al. A Human Colorectal Explant Culture to Evaluate Topical Microbicides for the Prevention of HIV Infection. J Infect Dis. 2005;192:1545–1556.
- Cummins JE, Jr, Guarner J, Flowers L, Guenthner PC, Bartlett J, et al. Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob Agents Chemother. 2007;51:1770–1779.
- Fuchs EJ, Lee LA, Torbenson MS, Parsons TL, Bakshi RP, et al. Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. J Infect Dis. 2007;195:703–710.
- Jennings R, Clegg A. The inhibitory effect of spermicidal agents on replication of HSV-2 and HIV-1 in-vitro. Journal of Antimicrobial Chemotherapy. 1993;32:71–82.
- Malkovsky M, Newell A, Dalgleish AG. Inactivation of HIV by nonoxynol-9. Lancet. 1988;1:645.
- Martin HL , Stevens CE, Richardson BA, Rugamba D, Nyange PM, et al. Safety of a nonoxynol-9 vaginal gel in Kenyan prostitutes. A randomized clinical trial. Sex Transm Dis. 1997;24:279–283.
- Roddy RE, Chutivongse S, Niruthisard S. The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Lancet. 1992;339:1371–1375.
- Rustomjee R, Abdool Karim Q, Abdool Karim SS, Laga M, Stein Z. Phase 1 trial of nonoxynol-9 film among sex workers in South Africa. AIDS. 1999;13:1511–1515.
- Van Damme L, Chandeying V, Ramjee G, Rees H, Sirivongrangson P, et al. Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. COL-1492 Phase II Study Group. AIDS. 2000;14:85–88.
- Kreiss J, Ngugi E, Holmes K, Ndinya-Achola J, Waiyaki P, et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA. 1992;268:477–482.
- Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, et al. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med. 1998;339:504–510.
- Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360:971–977.
- Beer BE, Doncel GF, Krebs FC, Shattock RJ, Fletcher PS, et al. In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother. 2006;50:713–723.
- Niruthisard S, Roddy RE, Chutivongse S. The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Sex Transm Dis. 1991;18:176–179.
- Patton DL, Cosgrove Sweeney YT, Rabe LK, Hillier SL. Rectal applications of nonoxynol-9 cause tissue disruption in a monkey model. Sex Transm Dis. 2002;29:581–587.
- Phillips DM, Taylor CL, Zacharopoulos VR, Maguire RA. Nonoxynol-9 causes rapid exfoliation of sheets of rectal epithelium. Contraception. 2000;62:149–154.
- Patel S, Hazrati E, Cheshenko N, Galen B, Yang H, et al. Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J Infect Dis. 2007;196:1394–1402.
- Kunjara Na Ayudhya RP, Billitto N, Rooney J, Dezzutti C. Influence of Semen on Efficacy of Tenofovir 1% Gel; Keystone Symposia: Prevention of HIV/AIDS 2009; Keystone, Colorado. Abst 233.
- Tien D, Schnaare RL, Kang F, Cohl G, McCormick TJ, et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses. 2005;21:845–853.
- Tabet SR, Surawicz C, Horton S, Paradise M, Coletti AS, et al. Safety and toxicity of nonoxynol-9 gel as a rectal microbicide. Sex Transm Dis. 1999;26:564–571.
- Van Damme L, Niruthisard S, Atisook R, Boer K, Dally L, et al. Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. AIDS. 1998;12:433–437.
- Phillips DM, Sudol KM, Taylor CL, Guichard L, Elsen R, et al. Lubricants containing N-9 may enhance rectal transmission of HIV and other STIs. Contraception. 2004;70:107–110.
- Harwood B, Meyn LA, Ballagh SA, Raymond EG, Archer DF, et al. Cervicovaginal colposcopic lesions associated with 5 nonoxynol-9 vaginal spermicide formulations. Am J Obstet Gynecol. 2008;198:32 e31–37.
- Fletcher PS, Elliott J, Grivel JC, Margolis L, Anton P, et al. Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS. 2006;20:1237–1245.
- Herrera C, Cranage M, McGowan I, Anton P, Shattock RJ. Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob Agents Chemother. 2009;53:1797–1807.
- Garcia-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008;5:e28.
- Anton P, Elliott J, Tanner K, Cho D, Johnson E, et al. Strong suppression of HIV-1 infection of colorectal explants following in vivo rectal application of UC781 gel: a novel endpoint in a Phase I trial. CROI 2009; Montreal, Canada. Abst 1067
Source: PubMed